ArticleLung cancer (Amsterdam, Netherlands)2021

Phase 1 multicenter study of the HSP90 inhibitor SNX-5422 plus carboplatin and paclitaxel in patients with lung cancers.

Martin Gutierrez et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.